Metabolic and obesity trials depend on patient-reported outcomes captured every day. Poor app design, burdensome login flows, and notification fatigue are the leading causes of ePRO dropout. Dropout in a long-duration GLP-1 trial is a protocol deviation, not just a missing data point.
Continuous glucose monitors, activity trackers, and smart scales generate data streams that need to flow into the EDC without manual transcription. Most platforms require custom integration work for each device. Castor supports direct data ingestion via open REST API.
Maintaining a parallel eCOA relationship means two contracts, two validation packages, two helpdesks, and a reconciliation process that adds weeks to every database lock. For a 52-week metabolic trial, that overhead compounds significantly.
GLP-1 and metabolic trials often run for 52 weeks or longer. Keeping patients engaged with the platform throughout requires a consumer-grade experience, not a clinical portal designed around site workflows.
GLP-1 and metabolic disease trials generate more daily patient data than almost any other therapeutic area. Weight measurements, dietary logs, physical activity, adverse events, and validated patient-reported quality-of-life outcomes must all be captured reliably, often for months or years. The industry default is to handle EDC and ePRO through separate vendors, creating a reconciliation problem that grows with every passing week of a long metabolic trial.
Castor Connect, our BYOD ePRO app, is designed around the patient experience first. Push notifications, intuitive interfaces, and short session formats are built for high-frequency capture. As a general platform capability, Castor has driven up to 95%+ daily ePRO compliance in large multinational Phase III trials (best case, not typical). For daily diary studies in GLP-1 and metabolic programs, that level of compliance matters directly to data completeness and endpoint validity.
Castor’s API-first architecture allows you to securely pull structured data from continuous glucose monitors (CGMs), wearables, and aggregators directly into the EDC via our open REST API. Combine objective device telemetry with subjective patient-reported outcomes in a single, unified database, without building custom vendor silos. Sponsors can route device data from third-party aggregators or direct device APIs (covering ecosystems including Garmin, Fitbit, and Dexcom via aggregator) straight into Castor EDC.
EDC and eCOA live in the same Castor database. Patient-reported outcomes flow directly into the study record with no data transfer, no reconciliation step, and no second validation package. One database. One audit trail. One database lock.
Castor comes pre-configured with 190+ validated instruments out of the box, including EQ-5D, SF-36, and PROMIS, the gold-standard assessments for metabolic trials. Deploy the instruments your protocol requires from day one, without the build time and licensing friction of legacy eCOA vendors.
GLP-1 is the fastest-growing therapeutic area in clinical research. Castor scopes each study build with managed Professional Services. Low-to-medium complexity studies typically move from kickoff (KOM) to user acceptance testing (UAT) in 4 to 8 weeks. High-complexity studies take 8 to 12 weeks. The platform is also designed to support long-term retention across the extended follow-up periods common in metabolic programs, with patient engagement tooling built to reduce dropout over 52-week and multi-year timelines.
Obesity and metabolic disease studies increasingly recruit globally. The Castor platform is available in 15-20 languages, supported by 24/7 multilingual patient support in 15-20 languages, with a single platform managing all markets and no per-country software instances required. For trials running in China, Castor also supports native WeChat eCOA, so participants complete assessments in an app they already use every day. Full regulatory compliance built in: FDA 21 CFR Part 11, ICH E6(R2/R3), EU Annex 11, GDPR, and HIPAA validated across all study types and jurisdictions.
Powering 140+ metabolic and endocrinology trials and 360+ cardiovascular trials globally. Castor supports long-duration outcomes research across the cardiometabolic spectrum, from interventional GLP-1 programs to large observational registries.
In two major endocrinology programs, Castor Catalyst automated EHR data ingestion and eliminated the manual transcription overhead that had consumed 40 hours of effort per patient. Time from patient enrollment to data appearing in the EDC dropped to just 1 hour.
Castor powered a multi-center Type 2 Diabetes cohort tracking vascular outcomes across 4,300+ patients. The kind of long-duration outcomes infrastructure that GLP-1 extension and cardiometabolic programs depend on.
Built for long-term retention in weight management research, Castor hosts a national bariatric surgery outcomes registry tracking 1,400+ patients longitudinally across extended follow-up.
Castor powers commercial digital health screening studies with 20,900+ participants capturing high-frequency digital endpoints, the same BYOD and device-data foundation that drives CGM and wearable integration in metabolic trials.
Recognized as a Major Contender in Everest Group’s Life Sciences eCOA Products PEAK Matrix® Assessment 2025.
Rated strongly for customer loyalty in ISR’s 2025 eCOA/ePRO Benchmarking.
Castor is a unified clinical trial platform for GLP-1 and metabolic disease research. It combines electronic data capture (EDC), eCOA/ePRO, and wearable device integration on a single database, supporting 18,000+ studies across 160+ countries. For high-frequency capture in obesity and metabolic trials, the BYOD patient app supports daily diaries and event-driven reporting, with validated instruments including EQ-5D, SF-36, and PROMIS pre-configured from day one. Because EDC and eCOA share the same database, patient-reported outcomes, daily diaries, and device data flow directly into the study record with no transfer step and no reconciliation overhead.
EDC and eCOA live together, so there is no separate vendor, no second validation package, and no reconciliation step between systems before a database lock.
CGMs, activity trackers, and smart scales are ingested via an open REST API and sit next to patient-reported outcomes in one real-time view.
Validated for FDA 21 CFR Part 11, ICH E6(R2/R3), EU Annex 11, GDPR, and HIPAA, with 15-20 languages for the 52-week and multi-year timelines common in metabolic programs.
Yes. Castor Connect, our BYOD ePRO app, is designed for high-frequency data capture including daily diaries, weekly assessments, and event-driven reporting. As a general platform capability, Castor has driven up to 95%+ daily ePRO compliance in large multinational Phase III trials (best case, not typical). For metabolic trials where ePRO forms part of the primary endpoint, that level of compliance is a scientific requirement, not just an operational preference.
Yes. Castor ingests device and wearable data via our open REST API. Rather than locking you into a closed vendor ecosystem, the platform allows sponsors to route device data from third-party aggregators or direct device APIs straight into Castor EDC, covering ecosystems including CGMs, activity trackers, and smart scales. This provides a unified, real-time view of both objective metabolic telemetry and patient-reported ePRO data in a single database.
No. Castor’s EDC and eCOA are on the same platform and the same database. Patient-reported outcomes, including 190+ validated instruments covering the gold-standard metabolic assessments, are captured directly within the EDC without a data transfer step. This eliminates the reconciliation overhead and additional vendor relationship that separate eCOA tools require.
Castor is designed for trials of any duration. Long-duration study features include ongoing patient engagement tooling, notification management, visit schedule flexibility, and a patient app experience designed to reduce dropout over extended participation periods. The platform is designed to support long-term retention across the 52-week and multi-year timelines common in GLP-1 and metabolic disease programs.
Castor is built for regulated metabolic research across global jurisdictions. The platform is validated for FDA 21 CFR Part 11, ICH E6(R2/R3), EU Annex 11, GDPR, and HIPAA across all study types. With 15-20 languages and a single platform managing every market, sponsors run multinational GLP-1 and obesity programs without standing up per-country software instances to meet local requirements.
Castor is built for regulated metabolic research across global jurisdictions. The platform is validated for FDA 21 CFR Part 11, ICH E6(R2/R3), EU Annex 11, GDPR, and HIPAA across all study types. With 15-20 languages and a single platform managing every market, sponsors run multinational GLP-1 and obesity programs without standing up per-country software instances to meet local requirements.